= Orders Today will be Shipped Tomorrow

<= td vAlign=3Dtop align=3Dleft width=3D277 rowspan=3D6 height=3D1>

<= font face=3D"Times New Roman" style=3D"font-size: 13pt"> = PROJECTIONS, = OBJECTIVES AND STATISTICS

	TOP 4 REASONS TO BUY WSCH=

1.	The products and medical therapies developed by WSCH rep= resent possibly the most important breakthrough in the field of Der= matology in the last fifty years.
2.	WSCH anticipat= es FDA approval on seven over-the-counter products within the next = year, which will provide significant revenue in the retail drug market.
3.<= /font>	WSCH has experienced a success rate of 90% during clinical studies, completely eliminating skin disease from 90% of= all patients treated.
4.	By year five, WSCH plan= s to have annualized revenue over $525 million and over $125 mil= lion in EBIT. This does not take into account income from OTC pr= oducts which will be substantial.

&= nbsp; &nb= sp; = ; &= nbsp; &nb= sp; = ; Over a five year period, AISC (WSCH's subsidiary) plans to establish = 350 clinics in over 100 major population areas. The company plans= to hire over 150 medical doctors for these clinics, train over 1,000 medi= cal assistants and treat over 2,000,000 patients. Also by year five= , WSCH plans to have annualized over $525 million in revenue and over $= 125 million in EBIT. This does not take into account income from OTC p= roducts which will be substantial. As of 1991, there were ap= proximately 14 million chronic acne and eczema patients annually in= the United States, with the highest percentage between 18 to 44 year= s of age. The actual number of patients with any type of acne Is= significantly higher. Seven billion dollars is spent annuall= y on dermatological pharmaceutical products for these disorders.<= /span> In 1994, the teen population reached 25 million. Duri= ng the next decade, it will grow at nearly twice the rate of = the overall population (according to U.S. Census Bureau projectio= ns). Acne patients are primarily teenagers, whereas eczema patie= nts range from infants to the elderly.

SYMBOL:=	&= nbsp; WSCH
&nbs= p; CURRENT PRICE:	$0.059
= ; 52 WEEK HIGH:	$27.50
&= nbsp; 52 WEEK LOW:	$0.056<= /b>

COMPANY BACKGROUND<= /font>

Wasatch Pharmaceutical, Inc. = is a fourteen year old company with a record of outstanding achievements i= n the field of Dermatology. Dermatology. Under the name of its subsid= iary, American Institute of Skin Care (AISC), Wasatch has operated = two prototype clinics for the last five years where the products and medic= al therapies have been tested and proven on hundreds of patients. The Comp= any's activities have been centered on research in the area of serious = skin diseases. A concurrent discov= ery and benefit is WSCH's dramatic success in the area of skin rejuvenatio= n.

Seeing the high growth potential from ma= jor funding, WSCH elected to become a public company less than two = years ago.

Wasatch's major success= es in the area of skin diseases include:

Cystic Acne, Eczema, Seborrhea, Contact Dermatitis, Molluscum, Folliculit= is, Acne Rosacea and less prevalent skin diseases.

Interestingly, these skin disorders account for more than 7= 0% of all business in the field of dermatology for which there are ver= y few (if any) safe, effective therapies like those developed by Wasatc= h.

Because the therapies developed by W= asatch dominate this area of medicine, WSCH has elected to market i= ts products via company-owned clinics throughout the United States. T= his decision has resulted in the establishment of two research clinics<= /b> in Utah for the purpose of implementing procedures within the clinics = pursuant to testing and confirming the results that were achieved in past = clinical trials. Due to its success rate of 90% on hundreds of p= atients over a five year period, WSCH's clinics are now on line with i= nsurance providers independent of HMOs. Efforts to establish Preferred Pro= vidership status with HMOs are presently being pursued.

<= /div>

MURRAY, Utah--(BUSINESS WIRE)--Nov. 27,= 2001--Wasatch Pharmaceutical Inc. (OTCBB:WSCH - news) CEO Gary Heesch announced today a marketing campaign dir= ected to physicians. A direct link has been established on a physician rec= ruiting Web site making available therapies for the treatment of cystic ac= ne, acne, folliculitis and skin rejuvenation. Physicians will find the ben= efits of these treatment therapies by logging on to the "X Acne&qu= ot; link at the Physician Search website. This physician search Web si= te typically receives over 200,000 hits per month. Mr. Heesch remin= ded, "Our treatment therapy products are also available via the AISC = Online Store."

Th= ese skin treatment products come in kit form providing a 90-day supply to = patients for the full treatment program. Included in the kit is an instruc= tional video on the treatment therapy allowing the patient to use these pr= oducts in their home. The therapies, when used as instructed, achieve a success rate of eradication in excess of 90% with no side effects of any = consequence. Previously, these therapies and associated products were = only available through the two prototype clinics in Utah. The availability= of these products will open the way for family practitioners, pediatricia= ns, internists and other primary care physicians to retain their patients = under their care during the treatment of these common skin disorders. T= he benefit to insurance providers is the potential to save millions of dol= lars in reimbursement costs by freeing the physician and the patient from = ongoing treatment.

In the = coming year, six additional therapies will be made available for a = broad range of skin disorders that are badly in need of successful therapi= es.

Gary Heesch also announced= the listing of Wasatch Pharmaceutical stock on the Frankfurt and Berli= n Exchanges in Germany. Active trading on these exchanges will take pl= ace upon the completion of a research report in Germany. Said Mr. Heesch, = "We feel this is a significant event as Wasatch will gain wider ex= posure as a leader in dermatology and will put buying pressu= re on its stock to reflect the true value of a company that has= committed years of research and development of products that allow people= with serious skin disorders to live normal and more productive lives.&quo= t;

There may be forward-lookin= g statements in this release. Investors are cautioned that such forward-lo= oking statements involve risks and uncertainties, including, without limit= ation, continued acceptance of the Company's products, increased levels of= competition, new products introduced by competitors, changes in the rates= of subscriber acquisition and retention, and other risks detailed from ti= me to time in the Company's periodic reports filed with the Securities and= Exchange Commission.

Wasatch Pharmaceu= tical Inc. Announces a New Physician Marketing Campaign and Listing On Ger= man Stock Exchanges